CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug (PR Newswire via Yahoo! Finance)
CEL-SCI CORPORATION announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated manufacturing facility for its cancer drug Multikine .

FDA Grants Tentative Approval for 50th and 51st Anti-Retroviral Drugs Under President's AIDS Relief Plan (U. S. Food and Drug Administration)
FDA granted tentative approval for nevirapine tablets, indicated for use with other antiretroviral agents for the treatment of HIV-1 infection, and for the pediatric triple fixed dose combination tablet of lamivudine, stavudine and nevirapine -- the first fixed dose anti-HIV product designed to treat children under the age of 12 years.

FDA taking no chances when it comes to drug safety (News-Medical-Net)
These days the U.S. Food and Drug Administration (FDA) is taking no chances when it comes to the safety of new drugs.